A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 6, 2004, Pages 519-527

  Fukami, Tatsuki ^b   Nakajima, Miki ^b   Yoshida, Ryoko ^b   Tsuchiya, Yuki ^b   Fujiki, Yuto ^b   Katoh, Miki ^b   McLeod, Howard L ^b   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; COUMARIN; COUMARIN 7 HYDROXYLASE; CYTOCHROME P450 2A6; NICOTINE; NICOTINE GUM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; ENZYME ACTIVITY; ESCHERICHIA COLI; EXON; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYDROXYLATION; INTRON; METABOLISM; MICHAELIS CONSTANT; NUCLEOTIDE SEQUENCE; OXIDATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VELOCITY; WILD TYPE;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; AMINO ACID SUBSTITUTION; ARYL HYDROCARBON HYDROXYLASES; CELL MEMBRANE; CHINA; DNA; EXONS; GENE FREQUENCY; GENOTYPE; HUMANS; INTRONS; ISOENZYMES; JAPAN; KOREA; MIXED FUNCTION OXYGENASES; NICOTINE; NICOTINIC AGONISTS; PLASMIDS; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UNITED STATES;

EID: 10044244648     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.08.014     Document Type: Article

References (38)

1. M. Nakajima, T. Yamamoto, K.-I. Nunoya, T. Yokoi, K. Nagashima, K. Inoue Role of human cytochrome P4502A6 in C-oxidation of nicotine Drug Metab Dispos 24 1996 1212 1217
2. M. Oscarson Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism Drug Metab Dispos 29 2001 91 95
3. K.-I. Nunoya, T. Yokoi, K. Kimura, T. Kainuma, K. Satoh, M. Kinoshita A new CYP2A gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride in humans J Pharmacol Exp Ther 289 1999 437 442
4. K.-I. Nunoya, T. Yokoi, Y. Takahashi, K. Kimura, M. Kinoshita, T. Kamataki Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of entire CYP2A6 gene associated with the poor metabolizer phenotype J Biochem 126 1999 402 407
5. M. Oscarson, R.A. McLellan, H. Gullsten, J.A.G. Agundez, J. Benitez, A. Rautio Identification and characterization of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism FEBS Lett 460 1999 321 327
6. M. Oscarson, R.A. McLellan, H. Gullusten, Q.Y. Yue, M.A. Lang, M.L. Bernal Characterization and PCR-based detection of a CYP2A6 gene deletion found at high frequency in a Chinese population FEBS Lett 448 1999 105 110
7. M. Nakajima, J.-T. Kwon, N. Tanaka, T. Zenta, Y. Yamamoto, H. Yamamoto Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans Clin Pharmacol Ther 68 2001 72 78
8. S. Yamano, J. Tatsuno, F.J. Gonzalez The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes Biochemistry 29 1990 1322 1329
9. K. Kitagawa, N. Kunugita, M. Kitagawa, T. Kawamoto CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity J Biol Chem 276 2001 17830 17835
10. N. Ariyoshi, Y. Sawamura, T. Kamataki A novel single nucleotide polymorphism altering stability and activity of CYP2A Biochem Biophys Res Commun 281 2001 810 814
11. S. Daigo, Y. Takahashi, M. Fujieda, N. Ariyoshi, H. Yamazaki, W. Koizumi A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur Pharmacogenetics 12 2002 299 306
12. R. Yoshida, M. Nakajima, Y. Watanabe, J.-T. Kwon, T. Yokoi Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism Br J Clin Pharmacol 54 2002 511 517
13. C. Xu, Y.S. Rao, E. Hoffmann, J. Jones, E.M. Sellers, R.F. Tyndale An in vivo pilot study characterizing the new CYP2A6*7,*8, and*10 alleles Biochem Biophys Res Commun 290 2002 318 324
14. M. Pitarque, O. von Richter, B. Oke, H. Berkkan, M. Oscarson, M. Ingelman-Sundberg Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity Biochem Biophys Res Commun 284 2001 455 460
15. R. Yoshida, M. Nakajima, K. Nishimura, S. Tokudome, J.-T. Kwon, T. Yokoi Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of mRNA and enzymatic activity in vivo an in vitro Clin Pharmacol Ther 74 2003 69 76
16. M. Oscarson, R.A. McLellan, V. Asp, M. Ledesma, M.L.B. Ruiz, B. Sinues Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity Hum Mutat 20 2002 275 283
17. Y. Rao, E. Hoffmann, M. Zia, L. Bodin, M. Zeman, E.M. Sellers, R.F. Tyndale Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking Mol Pharmacol 58 2000 747 755
18. D.F. Gu, L.J. Hinks, N.E. Morton, I.N.M. Day The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit Ann Hum Genet 64 2000 383 390
19. M. Miyamoto, Y. Umetsu, H. Dosaka-Akita, Y. Sawamura, J. Yokota, H. Kunitoh CYP2A6 gene deletion reduces susceptibility to lung cancer Biochem Biophys Res Commun 261 1999 658 660
20. W. Tan, G.-F. Chen, D.-Y. Xing, C.-Y. Song, F.F. Kadlubar, D.-X. Lin Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population Int J Cancer 95 2001 96 101
21. M. Nakajima, Y. Kuroiwa, T. Yokoi Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6 Drug Metab Rev 34 2002 865 877
22. C. Xu, S. Goodz, E.M. Sellers, R.F. Tyndale CYP2A6 genetic variation and potential consequences Adv Drug Deliv Rev 54 2002 1245 1256
23. H. Iwata, K.-I. Fujita, H. Kushida, A. Suzuki, Y. Konno, K. Nakamura High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli Biochem Pharmacol 55 1998 1315 1325
24. 5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli Prot Exp Purif 24 2002 329 337
25. T. Omura, R. Sato The carbon monoxide-binding pigment of liver microsomes J Biol Chem 239 1964 2370 2378
26. A. Bradford Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 1976 248 254
27. C.H. Williams Jr, H. Kamin Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver J Biol Chem 237 1962 587 595
28. Y. Yasukochi, B.S. Masters Some properties of detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography J Biol Chem 251 1976 5337 5344
29. A. Parikh, E.M. Gillam, F.P. Guengerich Drug metabolism by Escherichia coli expressing human cytochromes P450 Nat Biotechnol 15 1997 784 788
30. M. Nakajima, T. Yamamoto, K.-I. Nunoya, T. Yokoi, K. Nagashima, K. Inoue Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes J Pharmacol Exp Ther 277 1996 1010 1015
31. M. Nakajima, S.-I. Yamagishi, H. Yamamoto, T. Yamamoto, Y. Kuroiwa, T. Yokoi Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans Clin Pharmacol Ther 67 2000 57 69
32. M. Nakajima, R. Yoshida, T. Fukami, H.L. McLeod, T. Yokoi Novel human CYP2A6 alleles confound gene deletion analysis FEBS Lett 569 2004 75 81
33. M. Nakajima, T. Yamamoto, Y. Kuroiwa, T. Yokoi Improved highly sensitive method for determination of nicotine and cotinine in human plasma by high-performance liquid chromatography J Chromatogr B 742 2000 211 215
34. Human Cytochrome P450 (CYP) Allele Nomenclature Committee home page. Available from: URL:http://www.imm.ki.se/CYPalleles/. Accessed Sept 17, 2004.
35. D.F. Lewis Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes Arch Biochem Biophys 409 2003 32 44
36. P. Soucek Expression of cytochrome P450 2A6 in Escherichia coli: purification, spectral and catalytic characterization, and preparation of polyclonal antibodies Arch Biochem Biophys 370 1999 190 200
37. M. Nakajima, K. Ohyama, S. Nakamura, N. Shimada, H. Yamazaki, T. Yokoi Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes Drug Metab Dispos 27 1999 792 797
38. D.F.V. Lewis, M. Dickins, B.G. Lake, P.J. Eddershaw, M.H. Tarbit, P.S. Goldfarb Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity Toxicology 133 1999 1 33